Peter Hodgson

Australia & New Zealand Banking Group Ltd. provides banking, financial products and services to retail, small business, corporate and institutional clients. It operates its business through the following segments: Australia Retail and Commercial; Institutional; New Zealand; Pacific; and Technology, Services and Operations and Group Centre. The Australia segment comprises the retail and corporate and commercial business units which provides products and services to consumer and private banking customers in Australia via the branch network, mortgage specialists, the contact centres, a variety of self-service channels and and third party brokers; and banking services including traditional relationship banking and financial solutions through managers focusing on privately owned small, medium, and large enterprises as well as the agricultural businesses. The Institutional segment refers to the transaction banking, loans and specialised finance and markets solutions. The New Zealand segment refers to the retail and commercial business units. The Pacific segment offers products and services to retail customers, small to medium-sized enterprises, institutional customers and governments located in the Pacific Islands. The Technology, Services and Operations, and Group Centre segment provides support to the operating divisions including technology, operations, shared services, property, risk management, financial management, strategy, marketing, human resources and corporate affairs; as well as group treasury, shareholder functions, enablement functions and minority investments in Asia. The company was founded in 1835 and is headquartered in Docklands, Australia.

The Myer Family Investments Pty Ltd. (MFI) is a private investment firm whose shareholders are members of the Sidney and Merlyn Myer family and related entities. The firm was founded in 1986 and is headquartered in Melbourne, Australia. MFI provides long-term, patient and supportive capital and its investments are designed to support the financial future of the family and its philanthropic pursuits.

The Myer Family Co. Pty Ltd. (MFCo) is one arm of a multi-family office established in 1986 and based in Melbourne with a second office in Sydney, which opened in 2006. The firm is 75% owned by the Myer family, owners of an interest in the Myer chain of department stores (SY: MYR), and 25% by the Maple-Brown family, founders of the Maple-Brown Abbott funds management company. MFCo provides investment services to the members of the Myer family, whereas The Myer Family Office Ltd. provides wealth management and related services to the Myer family as well as to a clientele of ultra-high-net worth individuals, families, trusts, charities, foundations and corporations. MFCo's wealth management approach covers investment selection and management, portfolio administration, tax planning and accounting, cash flow planning, estate and inheritance planning, philanthropy services, trusts, pensions, insurance products, banking services and reporting.

Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia.

Save the Children Australia operates as a aid and development agency dedicated to helping children. It protects children from harm and help them access quality education and health services. The company was founded by Eglantyne Jebb in 1919 and is headquartered in Carlton, Australia.

Juicy Isle Pty Ltd. produces and markets fruit juice beverages. It also supplies a variety of snack food, beverages, and confectionery products. The company was founded in 1971 and is headquartered in Cambridge, Australia.

Save the Children International operates as an independent organization for children. The non-profit company is based in London, UK. The British company was founded in 1919 by Eglantyne Jebb and the CEO is Inger Ashing.

Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia.